In 2024, the drug teclistamab became the first bispecific antibody But the side effects can have a detrimental impact on patients
teclistamab-cqyv. All possible side effects are not included. Your side effects may be different depending on your cancer diagnosis, condition, or if you
Note: Each of the side effects above was reported in 20% or greater of patients treated with teclistamab-cqyv. All possible side effects are not included.
by T Alexander 2024The observed side effects are similar to those reported in patients with multiple myeloma who had received teclistamab. Teclistamab may also
Teclistamab, sold under the brand name Tecvayli, is a human bispecific monoclonal The most common side effects include hypogammaglobulinemia (low
risk of adverse effects (antagonistic effects; additive effects). CLOSE. sirolimus. 1 interaction. Tecvayli (teclistamab-cqyv) (teclistamab). sirolimus
What are the side effects of teclistamab-cqyv? ; Blood disorders including: Decrease in count of lymphocyte immune cells; Decrease in white blood
What are the side-effects of teclistamab? Neutropenia (64% of patients) Anaemia (37%) Thrombocytopenia 21%) Lymphopenia (32%) Infections (45%) Pneumonia (
Teclistamab-cqyv has been shown to be effective in a pivotal trial that demonstrated an overall response rate of more than 60% in heavily pretreated patients. Compared with other BCMA-targeted agents, the side effect profile of teclistamab-cqyv suggests a more tolerable option for elderly patients.
Comments
one of my own pet peeves, sorry